Patent Law Counselor Dr. Javier M. Mixco advises on life science and medical device patent prosecution and enforcement matters. He guides his clients through the often challenging process of identifying, patenting, and enforcing their patents and patent families.

Javier has over a decade of experience working with clients with biotechnical, chemical, pharmaceutical, and medical device developments. He enjoys collaborating with his clients to provide expert support with patent claiming, response strategy, clearance searches, validity and infringement opinions, due diligence, litigation support, and other post-grant matters. A natural coalition builder, Javier is particularly skilled in working with patent examiners to ensure his clients’ innovations are effectively and efficiently protected.

In the area of biotechnology, Javier is fluent in the science of gene therapy, immunologic and antibody therapies, vaccines, miRNA and RNAi techniques, neuroscience, and pharmaceuticals, among other examples. He also writes medical device patents for cardiovascular monitoring, pulmonary function monitoring, various imaging modalities, surgical equipment, defibrillators, and drug delivery systems. In addition, he has experience with design patents, agricultural cultivar patents, and other mechanical and electro-mechanical utility patents.

Javier’s keen interest in and passion for science, technology, and medicine led him to pursue an undergraduate degree in Biological Anthropology, an M.D., and a J.D. His deep understanding of the biotech and medical devices industries allows him to navigate the intricate details of these distinct sectors, ensuring the protection of his clients’ innovations and safeguarding their intellectual property rights.

Known for his meticulous attention to detail, analytical approach to problem-solving, and ability to speak the language of scientists, medical practitioners, and engineers alike, Javier leaves no stone unturned in pursuing and securing robust patents and patent families for his clients. His exceptional ability to dissect complex scientific concepts and translate them into compelling legal arguments and patents makes him an invaluable asset for clients seeking to patent and monetize their discoveries.

Beyond his biotechnical, medical, and legal expertise, Javier is appreciated for his strong work ethic and dedication to those he serves. He invests significant time in understanding the underlying business objectives inherent in patent law and practice and tailors his counsel accordingly. Javier never loses sight that patents are valuable commercial assets, and patent strategy is ultimately a business decision for his clients. He is valued for being forthright with his clients if he believes they are considering an action that is not in their best interest. His commitment to delivering exceptional results has earned him the respect and trust of both clients and colleagues.

Notably, during law school, Javier served as a judicial extern to Judge Dee Brown of the U.S. District Court of Utah and then Associate Chief Justice Durrant of the Utah Supreme Court. These experiences sharpened his strategic thinking and writing skills substantially. Before joining JMIN, Javier was a patent law associate at Bryan Cave Leighton Paisner, Seed IP Law Group, Smith & Hopen, Stoel Rives, and TaskBritt. Javier is fluent in Spanish.

Practice Areas


  • J.D., University of Utah S.J. Quinney College of Law with Honors
  • M.D., Duke University School of Medicine with Honors
  • A.B., Harvard University, cum laude


  • United States Patent and Trademark Office
  • California
  • Utah
  • Washington

Published Work

  • Javier Mixco, Cory Smith, and George Chen, What really doomed kidney test patents in Federal Circuit Ruling, LAW360. Dec. 2022
  • Elsersy H, Mixco J, Sheng H, Pearlstein RD, Warner DS, Selective gamma-aminobutyric acid type A receptor antagonism reverses isoflurane ischemic neuroprotection, ANESTHESIOLOGY. 2006 Jul; 105(1):81-90
  • Yokoo N, Sheng H, Mixco J, Homi HM, Pearlstein RD, Warner DS, Intraischemic nitrous oxide alters neither neurologic nor histologic outcome: a comparison with dizocilpine, ANESTH ANALG. 2004 Sep; 99(3):896-903
  • Homi HM, Mixco JM, Sheng H, Grocott HP, Pearlstein RD, Warner DS, Severe hypotension is not essential for isoflurane neuroprotection against forebrain ischemia in mice, ANESTHESIOLOGY. 2003 Nov; 99(5):1145-51